Clinical Trials Logo

Dyssomnias clinical trials

View clinical trials related to Dyssomnias.

Filter by:

NCT ID: NCT00585208 Terminated - Bipolar Disorder Clinical Trials

Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this research study is to evaluate the safety and efficacy of ramelteon (Rozeremâ„¢) as an add-on treatment for sleep problems in patients with bipolar disorder. This study will determine whether or not the addition of ramelteon to ongoing medication(s) for bipolar disorder is useful in improving sleep.

NCT ID: NCT00462254 Terminated - Parkinson's Disease Clinical Trials

Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease

Start date: June 2007
Phase: Phase 4
Study type: Interventional

Patients with Parkinson's disease represent a significant proportion of VA elderly patients. Sleep disturbances and caregiver burnout association with this condition represent a significant problem. In this study, the investigators propose to perform an evaluation of a fixed doe of ramelteon on sleep in VA outpatients diagnosed with Parkinson's disease. The hypothesis to be examined is that ramelteon will improve the quality of sleep in patients with Parkinson's disease while indirectly improving the quality of life for the patients and caregivers. The investigators further hypothesize that these changes will occur through restructuring and normalization of the sleep architecture.

NCT ID: NCT00202449 Terminated - Clinical trials for Stress Disorders, Post-Traumatic

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

Start date: July 2004
Phase: N/A
Study type: Interventional

The purposes of this study are: - to evaluate the efficacy and tolerability of the drug prazosin compared to placebo for combat stress-related nightmares, sleep disturbance and overall function in recently combat-exposed returnees from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF). - to evaluate the effects of the selective serotonin reuptake inhibitor (SSRI) paroxetine on behavioral symptoms and overall function in this population.